Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Articles

Vol. 2 No. 3 (2011): July – September 2011

Quantitative Structure Metabolism Relationship (QSMR): Comparative Molecular Field Analysis of CYP2D6 Substrates

DOI
https://doi.org/10.37285/ijddd.2.3.2
Submitted
December 9, 2024
Published
2024-12-09

Abstract

Comparative molecular field analysis (CoMFA) was performed for CYP2D6 substrates. The CoMFA model was built from the data set of substrates undergoing different CYP2D6 mediated metabolic reactions. The developed model has proven to be predictive, with cross validated correlation coefficient (q2) of 0.531 and non-cross validated correlation coefficient (r2) of 0.969. CoMFA model was also validated with independent test set of substrates which are not involved in model building. The obtained model helps to understand the stereoelectronic structural features that are responsible for the CYP2D6 mediated metabolism. The information obtained from contour maps of CoMFA could be useful to design a therapeutic analogues with improved metabolic profile toward CYP2D6.

References

  1. [1] Guengerich, F.P.; MacDonald, J.S. Chem. Res. Toxicol. 2007, 20, 344-369.
  2. [2] Ortiz de Montellano, P.R. Cytochrome P450: structure, mechanism and biochemistry, 3rd Ed., Kluwer Academic/Plenum Publishers, New York, 2005, pp 1-7
  3. [3] Goeptar, A.R.; Scheerens, H.; Vermeulen, N.P.E. CRC Crit. Rev. Toxicol. 1995, 25, 25-65.
  4. [4] Guengerich, F.P. Drug Metab. Rev. 2004, 36, 159-197.
  5. [5] Ahlström, M.M.; Ridderström, M.; Zamora, I.; Luthman, K. J. Med. Chem. 2007, 50, 4444-4452.
  6. [6] Yu, J.; Paine, M.J.I.; Maréchal, J.D.; Kemp, C.A.; Ward,C.J.; Brown, S.; Sutcliffe, M.J.; Roberts, G.C.K.; Rankin,E.M.; Wolf, C.R. Drug Metab. Dispos. 2006, 34, 1386-1392.
  7. [7] Rowland, P.; Blaney, F.E.; Smyth, M.G.; Jones, J.J.; Leydon, V.R.; Oxbrow, A.K.; Lewis, C.J.; Tennant,M. G.; Modi, S.; Eggleston, D.S. J. Biol. Chem. 2006, 281, 7614-7622.
  8. [8] Rendic, S.; Carlo, F.J.D. Drug Metab. Rev. 1997, 29,413-580.
  9. [9] Lewis, D.F.V. Toxicol. In Vitro. 2004, 18, 89-97.
  10. [10] Ekins, S.; Bravi, G.; Binkley, S.; Gillespie, J.S.; Ring,B. J.; Wikel, J.H.; Wrighton, S.A. Pharmacogenetics. 1999, 9, 477-489.
  11. [11] Koymans, L.; Vermeulen, N.P.E.; Van Acker, S.A.B.E.; Te Koppele, J.M.; Heykants, J.J.P.; Lavrijsen, K.; Meuldermans, W.; Donne-Op den Kelder, G.M. Chem. Res. Toxicol. 1992, 5, 211-219.
  12. [12] Hritz, J.; de Ruiter, A.; Oostenbrink, C. J. Med. Chem. 2008, 51, 7469-7477.
  13. [13] Haji-Momenian, S.; Rieger, J.M.; Macdonald, T.L.; Brown, M.L. Bioorg. Med. Chem. 2003, 11, 5545-5554.
  14. [14] SYBYL version 6.9, Tripos Inc., 1699 South Hanley Road, St Louis, MO 63144, USA, 2007.
  15. [15] Haji-Momenian, S.; Rieger, J.M.; Macdonald, T.L.; Brown, M.L. Bioorg. Med. Chem. 2003, 11, 5545-5554.
  16. [16] Cramer, R.D. J. Am. Chem. Soc. 1988, 110, 5959-5967.
  17. [17] Halgren, T.A. J. Am. Chem. Soc. 1990, 112, 4710-4723.
  18. [18] Golbraikh, A.; Tropsha, A. J. Mol. Graph. Model. 2002, 20, 269-276.
  19. [19] Senthil Kumar, P.; Bharatam, P.V. Med. Chem. Res. 2010, 19, 1121-1140.
  20. [20] Venhorst, J.; Onderwater, R.C.A.; Meerman, J.H.N.; Commandeur, J.N.M.; Vermeulen, N.P.E. Drug Metab. Dispos. 2000, 28, 1524-1532.
  21. [21] Raghavan, N.; Zhang, D.; Zhu, M.; Zeng, J.; Christopher,L. Drug Metab. Dispos. 2005, 33, 203-208.
  22. [22] Ohyama, K.; Nakajima, M.; Nakamura, S.; Shimada, N.; Yamazaki, H.; Yokoi, T. Drug Metab. Dispos. 2000, 28, 1303-1310.
  23. [23] Olesen, O.V.; Linnet, K. Pharmacology. 1997, 55, 235-243.
  24. [24] Olesen, O.V.; Linnet, K. Pharmacology. 1999, 59, 298-309.
  25. [25] Olesen, O.V.; Linnet, K. J. Clin. Psychopharmacol. 2000, 20, 35-42.
  26. [26] Linnet, K.; Olesen, O.V. Drug Metab. Dispos. 1997, 25, 1379-1382.
  27. [27] Lightfoot, T.; Ellis, S.W.; Mahling, J.; Ackland, M.J.; Blaney, F.E.; Bijloo, G.J.; De Groot, M.J.; Vermeulen, N.P.E.; Blackburn, G.M.; Lennard, M.S. Xenobiotica. 2000, 30, 219-233.
  28. [28] von Moltke, L.L.; Greenblatt, D.J.; Giancarlo, G.M.; Granda, B.W.; Harmatz, J.S.; Shader, R.I. Drug Metab. Dispos. 2001, 29, 1102-1109.
  29. [29] Ring, B.J.; Eckstein, J.A.; Gillespie, J.S.; Binkley,S.N.; VandenBranden, M.; Wrighton, S.A. J. Pharmacol. Exp. Ther. 2001, 297, 1044-1050.
  30. [30] Margolis, J.M.; O'Donnell, J.P.; Mankowski, D.C.; Ekins, S.; Obach, R.S. Drug Metab. Dispos. 2000, 28, 1187-1191.
  31. [31] Kim, K.A.; Chung, J.; Jung, D.H.; Park, J.Y. Eur. J. Clin. Pharmacol. 2004, 60, 575-581.
  32. [32] Desta, Z.; Wu, G.M.; Morocho, A.M.; Flockhart, D.A. Drug Metab. Dispos. 2002, 30, 336-343.
  33. [33] Venhorst, J.; Onderwater, R.C.A.; Meerman, J.H.N.; Commandeur, J.N.M.; Vermeulen, N.P.E. Drug Metab. Dispos. 2000, 28, 1524-1532.
  34. [34] Wienkers, L.C.; Wynalda, M.A. Drug Metab. Dispos. 2002, 30, 1372-1377.
  35. [35] Desta, Z.; Ward, B.A.; Soukhova, N.V.; Flockhart, D.A.J.Pharmacol. Exp. Ther. 2004, 310, 1062-1075.
  36. [36] Otton, S.V.; Ball, S.E.; Cheung, S.W.; Inaba, T.; Rudolph, R.L.; Sellers, E.M. Br. J. Clin. Pharmacol. 1996, 41, 149-156.
  37. [37] Springer, D.; Staack, R.F.; Paul, L.D.; Kraemer, T.; Maurer, H.H. Xenobiotica. 2005, 35, 227-237.
  38. [38] Springer, D.; Paul, L.D.; Staack, R.F.; Kraemer, T.; Maurer, H.H. Drug Metab. Dispos. 2003, 31, 979-982.
  39. [39] He, K.; Woolf, T.F.; Kindt, E.K.; Fielder, A.E.; Talaat, R.E. Biochem. Pharmacol. 2001, 62, 191-198.
  40. [40] Voorman, R.L.; Maio, S.M.; Hauer, M.J.; Sanders, P.E.; Payne, N.; Ackland, M.J. Drug Metab. Dispos. 1998, 26,631-639.
  41. [41] Fischer, V.; Vogels, B.; Maurer, G.; Tynes, R.E. J. Pharmacol.Exp. Ther. 1992, 260, 1355-1360.
  42. [42] Staack, R.F.; Paul, L.D.; Springer, D.; Kraemer, T.; Maurer, H.H. Biochem. Pharmacol. 2004, 67, 235-244.

Similar Articles

<< < 1 2 

You may also start an advanced similarity search for this article.